<DOC>
	<DOC>NCT01283542</DOC>
	<brief_summary>This study will assess pasireotide LAR efficacy on patients with non-functioning pituitary adenomas concerning tumor growth.</brief_summary>
	<brief_title>Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.</brief_title>
	<detailed_description />
	<mesh_term>Adenoma</mesh_term>
	<mesh_term>Pituitary Diseases</mesh_term>
	<mesh_term>Pituitary Neoplasms</mesh_term>
	<criteria>Nonfunctioning pituitary adenoma â‰¥ 1cm, patients without any previous treatment for the tumor Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Patients who require a surgical intervention for relief of any sign or symptom associated with tumor compression Previous pituitary surgery Previous medical treatment for pituitary tumor Patients who have received pituitary irradiation within 10 years prior to randomization Prolactin (PRL) levels &gt; 100 ng/mL. PRL evaluation should be performed with diluted samples to make sure to avoid the "hook effect." Patients presenting prolactinomas, acromegaly or Cushing's disease Patients with compression of the optic chiasm causing acute clinically significant visual field defects Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Non-functioning pituitary adenoma,</keyword>
	<keyword>pasireotide LAR,</keyword>
	<keyword>tumor volume</keyword>
</DOC>